MedTrace Logo

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

NCT06313008 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-11-29

No results posted yet for this study

Summary

We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac function, in patients with type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

Empagliflozin 10 MG

eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).

DRUG

Vildagliptin 50 MG

eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Lamiaa Khedr, Prof. · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2024-09-30
Completion
2024-10-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06313008 on ClinicalTrials.gov